BioCurex: Aggressively Moves Ahead with 2004 Strategic Plan.Business Editors RANCHO ran·cho n. pl. ran·chos Southwestern U.S. 1. A hut or group of huts for housing ranch workers. 2. A ranch. SANTA MARGARITA Santa Margarita ("Saint Margaret") may refer to:
Dr. Ricardo Moro, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , BioCurex Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BOCX) released the company's corporate forecast for 2004. The core of BioCurex's technology is the discovery and subsequent patenting related to a molecule found on cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer that is practically absent from normal cells or benign tumor benign tumor n. A tumor that does not metastasize or invade and destroy adjacent normal tissue. Benign tumor An abnormal proliferation of cells that does not spread to other parts of the body. cells. The molecule serves as a cancer "marker" that is found on the surface as well as inside a cancer cell. The company has called it RECAF(TM). Initially, the company developed and reported on a tissue test (Histo-RECAF) and received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. recognition for its ability to detect cancer cells. The product development and subsequent approval provided early proof of concept for its technology. In 2003, the company developed and tested a blood test for RECAF(TM) that is unparalleled in its ability to detect many types of cancer with 90% sensitivity and 95% specificity in the cancers the company has studied to date. No other company can make this claim; BioCurex has superb technology. The types of malignancies in which the assay has been shown to work cover 60% of all types of cancers. Therefore, it is reasonable to suggest that the Serum-RECAF(TM) test could find use in general screening of many populations, enabling an early diagnosis of any of these cancers. Early detection is the key to providing improved prognosis for all cancer patients. Further, the test should find early use in the monitoring of cancer patients who have received treatment, but who must be regularly evaluated for any recurrence recurrence /re·cur·rence/ (-ker´ens) the return of symptoms after a remission.recur´rent re·cur·rence n. 1. of cancer. Strategic Plan for 2004 -- Results from Japanese and French tests for Histo-RECAF biopsy test expected shortly -- Continued testing of various cancer types with the company's RECAF technology with timely reporting of results -- Discussions currently underway for licensing of BioCurex technologies with strategic alliance partners -- Expansion of specific non-disclosure agreements A non-disclosure agreement (NDA), also called a confidential disclosure agreement (CDA), confidentiality agreement or secrecy agreement, is a legal contract between at least two parties that outlines confidential materials or knowledge the parties with well-established potential licensees for the exchange of data. -- Intent to finalize fi·nal·ize tr.v. fi·nal·ized, fi·nal·iz·ing, fi·nal·iz·es To put into final form; complete or conclude: "They have jointly agreed ... -- in 2004 -- a major licensing deal as well as deals with smaller companies for niche applications of the company's unique technology. -- Directors and Officers will continue taking shares or options in lieu of salary to maintain cash for research and development. -- Realization of further patents for over 40 claims granted or pending in over 20 countries. (A RECAF patent for China was granted in late 2003) Other patents previously secured in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , Australia and Russia. -- Continued research and development for enhancement of the company's products. -- Planned use of the facilities of large licensees to acquire FDA approval where applicable. Allows their well established pipelines to expedite the process. Approvals for diagnostic tests take place in short time frames -- Once RECAF has developed licensing relationships for its proprietary diagnostic tests, more efficacies will be developed for cancer therapy and management. -- Minimal competition identified due to proprietary nature of BioCurex's technology as well as patent protections in place. BioCurex has worked diligently and progressively to develop, test and improve its technology. The company has demonstrated unique ability to detect various cancers with a blood test -- something which has not been possible to date in the world community. In a number of cases, BioCurex has been approached directly by well-established medical testing companies to engage in substantive strategic alliance and/or licensing discussions. The company expects that trend to continue and increase as its products gain more exposure within the medical and oncological communities. To read more regarding the state of the company, kindly visit its Web site at www.biocurex.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion